Get the Latest Investment Ideas Delivered Straight to Your Inbox.

TICKERS: MTNB

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy
Research Report

Source:

A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset.

In a March 21 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:OTC.MKTS) is "positioned for success" following its equity raise, "executed under favorable terms." Expected gross proceeds are $30 million plus any capital generated from the underwriters' option.

This raise is significant, Isaacson highlighted, because Matinas now has the finances it needs to advance its lead omega-3 asset MAT-9001 for severe hypertriglyceridemia through pivotal clinical trials toward a U.S. Food and Drug Administration approval.

To that end, Matinas intends to conduct a Phase 3 trial to evaluate MAT-9001 against a placebo, in which the primary endpoint will be lower triglyceride levels.

The company also aims to prove in the clinic that MAT-9001 stands out from approved and competitive products. "A small Phase 2 trial showed that the bioavailability and overall profile of MAT-9001 may give it a favorable position compared to Amarin's Vascepa," Isaacson noted.

However, Matinas plans to conduct another pharmacokinetic/pharmacodynamic head-to-head study, a larger one, for additional proof of MAT-9001's distinctive properties. "Based on previous Phase 2 data, we believe in the potential for this trial to generate differentiating data for MAT-9001," commented Isaacson.

In other news, Matinas recently added cardiovascular expert Dr. James J. Ferguson to its clinical team as chief medical officer.

ROTH's valuation on Matinas is based on approval in 2023 of MAT-9001 for hypertriglyceridemia in 2023 and pricing to begin at $1,100 per patient, per year. Accordingly, the investment banking firm has a Buy rating and a $4.45 per share target price on Matinas, whose stock is currently trading at around $1.13 per share.

[NLINSERT]

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, Matinas BioPharma Holdings Inc., Company Note, March 21, 2019

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of Matinas BioPharma Holdings, Inc. and as such, buys and sells from customers on a principal basis.

A Research Analyst and/or a member of the Analyst's household own(s) debt or equity securities of Matinas BioPharma Holdings, Inc. stock.

Shares of Matinas BioPharma Holdings, Inc. may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.




Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe